Nevertheless, in the last decade, targeting angiogenesis with vascular endothelial growth factor (VEGF) inhibitors (VEGFi) has improved clinical outcomes in patients with advanced HCC [8,9,10]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.